Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitiglinide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 7/20 | 0.50 |
| ▸ | CPA3 | P15088 | 3/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitiglinide SCHEMBL1219700 | 1.00 | CPA1 (0.50) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047718 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6135224 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL6496289 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL305840 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL3226695 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL4181526 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL9047711 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL2006146 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 | |
| Mitiglinide SCHEMBL14151746 | 0.99 | CPA1 (0.51) | CPA1CPA3CPB1CPB2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| CN-118948849-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| EP-4400105-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | claimed |
| CN-118215478-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-06-18 | — | — | CN | claimed |
| WO-2023038039-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | 塩野義製薬株式会社 | 2023-03-16 | — | — | WO | claimed |
| EP-3787631-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | Emory University (US) | 2021-03-10 | — | — | EP | claimed |
| CN-112334137-A | Orphan nuclear receptor modulators for NASH and other metabolic disorders | 埃默里大学 | 2021-02-05 | — | — | CN | claimed |
| US-8399418-B2 | Monosebacate of pyrazole derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-03-19 | — | — | US | claimed |
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | claimed |
| US-7666899-B2 | Pharmaceutical composition for treatment of lipid metabolism disorder | Kissei Pharmaceutical, Co. Ltd. (JP) | 2010-02-23 | — | — | US | claimed |
| EP-2136844-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | Centre De Recherche Sur Les Biotechnologies Marine (CA) | 2009-12-30 | — | — | EP | claimed |
| US-20090311321-A1 | ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-17 | — | — | US | claimed |
| EP-2050448-A1 | ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | claimed |
| US-20090030063-A1 | Combined pharmaceutical preparation for treatment of type 2 diabetes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-01-29 | — | — | US | claimed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | claimed |
| US-20080021086-A1 | Pharmaceutical Composition for Prevention or Treatment of Lipid Metabolism Disorder | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| EP-1872781-A1 | COMBINED PHARMACEUTICAL PREPARATION FOR TREATMENT OF TYPE 2 DIABETES | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-01-02 | — | — | EP | claimed |
| US-20070254938-A1 | Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease | KISSEI PHARMACEUTICA CO., LTD. (JP) | 2007-11-01 | — | — | US | claimed |
| EP-1757287-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF LIPID METABOLISM DISORDER | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021086-A1 | Pharmaceutical Composition for Prevention or Treatment of Lipid Metabolism Disorder | LIPA, PNLIP, LIPC | CPA1 1360/4885CPA3 945/4885CPB1 1163/4885 |
| US-20070254938-A1 | Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease | VEGFA, MMP1, SP1 | CPA1 612/4885CPA3 166/4885CPB1 431/4885 |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | PNLIP, LIPC, GPR119 | CPA1 1045/4885CPA3 1543/4885CPB1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.